EGFR and metastatic neoplasm: In patients with metastatic disease and activating EGFR mutations treated with EGFR inhibitors, there was no numerical difference in progression-free survival between patients on first-generation (erlotinib and gefitinib) or third-generation (osimertinib) EGFR inhibitors.